Membrane progesterone receptors β and γ have potential as prognostic biomarkers of endometrial cancer

• Published in: The Journal of steroid biochemistry and molecular biology 2018-04, Vol.178, p.303-311
• Main Authors: Sinreih, Maša, Knific, Tamara, Thomas, Peter, Frković Grazio, Snježana, Rižner, Tea Lanišnik
• Format: Article
• Language: English
• Subjects: Adenocarcinoma, Mucinous - genetics; Adenocarcinoma, Mucinous - metabolism; Adenocarcinoma, Mucinous - pathology; Alternative progesterone signaling; Biomarkers, Tumor - genetics; Biomarkers, Tumor - metabolism; Cell Membrane - metabolism; Cystadenocarcinoma, Serous - genetics; Cystadenocarcinoma, Serous - metabolism; Cystadenocarcinoma, Serous - pathology; Endometrial cancer; Endometrial Neoplasms - genetics; Endometrial Neoplasms - metabolism; Endometrial Neoplasms - pathology; Female; Humans; Membrane progesterone receptor; Middle Aged; mPR; Neoplasm Invasiveness; Nerve Tissue Proteins - genetics; Nerve Tissue Proteins - metabolism; PAQR; Progesterone action; Receptors, Progesterone - genetics; Receptors, Progesterone - metabolism
• ISSN: 0960-0760; 1879-1220
• DOI: 10.1016/j.jsbmb.2018.01.011

[Display omitted] •Expression of PAQR7 and PAQR8 is down-regulated in endometrial cancer.•Higher levels of PAQR5 correlate with lower FIGO stage.•Levels of the mPRγ protein are higher in cancer, compared to control endometrium.•Lower levels of the mPRβ protein are associated with more invasive cancer. Endometrial cancer (EC) is one of the most common malignancies in women worldwide. EC is linked to chronic exposure to estrogens that is unopposed by protective effects of progesterone. Progesterone modulates gene expression via classical nuclear receptors, and has rapid effects via the less characterized membrane-bound progesterone receptors (mPRs) of the progestin and adipoQ receptor (PAQR) family. The presence of mPRs in EC has not been investigated to date. The aims of this study were to examine PAQR7, PAQR8 and PAQR5, which encode for mPRα, mPRβ and mPRγ, respectively, for their expression and localization in EC tissue and adjacent control endometrium. Our results reveal decreased expression of PAQR7 and PAQR8, and unaltered expression of PAQR5 in EC versus control tissue. Expression of PAQR5 was decreased in EC with higher FIGO stage versus stage IA. Immunohistochemistry revealed lower levels of mPRα and mPRβ, but higher levels of mPRγ, in EC versus control tissue. There was greater decrease in mPRβ levels in tumors with lymphovascular invasion. The analysis of the expression data associates higher PAQR5 mRNA and mPRβ protein levels with favorable patient prognosis. Immunohistochemistry showed diverse localizations of mPRs in control and cancer endometrium. In control endometrium, mPRα and mPRβ were localized mostly at the cell membranes, while mPRγ was localized in the cytoplasm and/or nucleus. In cancer endometrium, mPRα and mPRβ were detected at the cell membrane or in the cytoplasm, or both, while mPRγ was only localized in the cytoplasm. Taken together, these results imply that mPRs are involved in EC pathogenesis through effects on the development or progression of cancer. The potential role of mPRβ and mPRγ as prognostic biomarkers needs to be further assessed on a larger number of samples.